AbbVie Inc. Stock
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
AbbVie Inc. | -0.970% | -2.844% | -9.674% | 11.064% | 8.765% | 64.238% | 115.287% |
Pfizer Inc. | 5.320% | -2.037% | -6.621% | -31.980% | -7.874% | -25.222% | -29.991% |
Elanco Animal Health Inc. | -2.010% | -0.869% | -17.497% | 43.492% | -8.831% | -53.275% | - |
Biogen Inc. | 1.190% | 6.730% | 1.104% | -27.082% | -14.589% | -9.463% | -0.983% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on the provided financial statements, AbbVie Inc., a prominent company in the pharmaceutical industry, appears to be maintaining a strong financial position. The company has demonstrated consistent growth in revenues and net income over the years. However, there are also challenges in certain aspects that could impact the company's financial health.
Revenue growth: From 2020 to 2022, AbbVie's total revenues increased from €45.8 billion to $58.0 billion, signifying a healthy growth rate. This suggests a strong demand for their products and services in the pharmaceuticals industry.
Net income growth: Net income has shown a steady increase. In 2020, the net income stood at €4.6 billion, which rose to €11.5 billion in 2021 and further increased to $11.8 billion in 2022.
Comments
News
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
AbbVie Inc. (NYSE: ABBV) stock is recovering after falling over 4% in the week preceding its earnings report on April 26, 2024. As the market closed on Monday, April 29, ABBV stock posted a gain
Better Dividend Stock: AbbVie or Johnson & Johnson?
There are many dividend stocks on the market, but few are as prominent as AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). These companies have raised their payouts for over 50 consecutive
3 Dividend Stocks to Buy and Hold for the Next Decade
Buy, hold, rake in solid income. That sounds like a pretty good investing strategy. You only have to find the right stocks worthy of holding for the long term and that pay attractive dividends.